Physician profile
Haytham Mously
NPI 1992156145
$16,814.83
in general payments reported to CMS, 2019-2025
15 companies · $47.20 in 2025
The $47.20 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $447 · 2021: $15K · 2022: $646 · 2023: $292 · 2024: $54.03 · 2025: $47.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15,375.99 | 2021-2023 | Onyx Frontier, In.Pact Admiral, In.Pact Av |
| Medtronic Vascular, INC. | $331.33 | 2019-2020 | |
| Abbott Laboratories | $327.89 | 2019-2024 | Jeti Peripheral Catheter, Perclose Prostyle |
| Boston Scientific Corporation | $287.86 | 2022-2023 | |
| Pfizer INC. | $221.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $53.03 | 2019-2021 | |
| Amgen INC. | $52.06 | 2021-2022 | |
| Stryker Corporation | $47.20 | 2025 | Artix Mt |
| Cardiovascular Systems INC. | $20.47 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.43 | 2021 | |
| Lundbeck LLC | $17.81 | 2019 | |
| Merck Sharp & Dohme LLC | $17.18 | 2023 | Verquvo |
| Genzyme Corporation | $16.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.82 | 2021 | |
| Esperion Therapeutics, INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haytham Mously listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.